The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FOLFOX versus FOLFOX plus nivolumab and ipilimumab administered in parallel or sequentially versus FLOT plus nivolumab administered in parallel in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase 2 trial of the AIO.
 
Sylvie Lorenzen
No Relationships to Disclose
 
Peter C. Thuss-Patience
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Meyers-Squibb; Daiichi Sankyo; Lilly; Merck KGaA; Merck Serono; Novartis; Pfizer; Roche
Research Funding - Merck/Pfizer (Inst)
 
Jorge Riera Knorrenschild
No Relationships to Disclose
 
Eray Goekkurt
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Roche; Sanofi
 
Tobias Nicolaas Dechow
No Relationships to Disclose
 
Ralf-Dieter Hofheinz
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Medac; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Sanofi/Aventis; SERVIER
 
Kim Barbara Luley
No Relationships to Disclose
 
Thomas Jens Ettrich
Consulting or Advisory Role - AstraZeneca; Bayer; BMS GmbH & Co. KG; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Eisai; Incyte; Ipsen; Lilly; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Baxalta/Shire
Travel, Accommodations, Expenses - Ipsen
 
Daniel Pink
Speakers' Bureau - PharmaMar (Inst)
Research Funding - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
 
Udo Lindig
No Relationships to Disclose
 
Gunnar Folprecht
Honoraria - Bristol-Myers Squibb; Lilly/ImClone; Merck KGaA; Merck Sharp & Dohme; Roche/Genentech; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Mundipharma; Roche/Genentech; Sanofi/Aventis; SERVIER
Research Funding - Merck KGaA
 
Gunter Schuch
No Relationships to Disclose
 
Michael Bitzer
Consulting or Advisory Role - Bayer/Vital; Bristol-Myers Squibb; Incyte; MSD Sharp & Dome GmbH; Roche Pharma AG
 
Claus Bolling
No Relationships to Disclose
 
Nils Homann
Consulting or Advisory Role - Amgen; BMS GmbH & Co. KG; Lilly; MSD Oncology; SERVIER
 
Sabine Junge
No Relationships to Disclose
 
Claudia Pauligk
No Relationships to Disclose
 
Timo Gaiser
No Relationships to Disclose
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Institut für Klinische Krebsforschung GmbH
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Lilly; MacroGenics; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Immutep; Ipsen; Lilly; Medac; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma